一二三四区视频,亚洲少妇熟女色,日本久热无码视频网,欧美国产日韩大尺度,亚洲a视频,久久少妇一区二区,日韩999无码视频,刺激久久久久久久,啊啊啊啊不要啊在线

ChemicalBook >> journal list >> The Lancet Regional Health: Western Pacific >>article
The Lancet Regional Health: Western Pacific

The Lancet Regional Health: Western Pacific

IF: 7.59
Download PDF

Efficacy and safety of SIM0417 (SSD8432) plus ritonavir for COVID-19 treatment: a randomised, double-blind, placebo-controlled, phase 1b trial

Published:1 September 2023 DOI: 10.1016/j.lanwpc.2023.100835 PMID: 37484496
Fuxiang Wang , Wen Xiao , Yimin Tang , Mengli Cao , Dan Shu , Tetsuya Asakawa , Yechun Xu , Xiangrui Jiang , Leike Zhang , Wei Wang , Jianxing Tang , Yuansheng Huang , Yang Yang , Yumei Yang , Renhong Tang , Jingshan Shen , Hongzhou Lu

Abstract

Background

SIM0417 (SSD8432) is an orally administered coronavirus main proteinase (3CLpro) inhibitor with potential anti-SARS-CoV-2 activity. This study aimed to evaluate the efficacy and safety of SIM0417 plus ritonavir (a pharmacokinetic enhancer) in adults with COVID-19.

Methods

This was a randomised, double-blind, placebo-controlled, phase 1b study in China. Adults with asymptomatic infection, mild or moderate COVID-19 were randomly assigned (3:3:2) to receive either 750?mg SIM0417 plus 100?mg ritonavir, 300?mg SIM0417 plus 100?mg ritonavir or placebo every 12?h for 10 doses. The main efficacy endpoints included SARS-CoV-2 viral load, proportion of participants with positive SARS-CoV-2 nucleic acid test and time to alleviation of COVID-19 symptoms. This trial is registered with ClinicalTrials.gov, NCT05369676.

Findings

Between May 12 and August 29, 2022, 32 participants were enrolled and randomised to high dose group (n?=?12), low dose group (n?=?12) or placebo (n?=?8). The viral load change from baseline in high dose group was statistically lower compared with placebo, with a maximum mean difference of??2.16?±?0.761 log10 copies/mL (p?=?0.0124) on Day 4. The proportion of positive SARS-CoV-2 in both active groups were lower than the placebo. The median time to sustained alleviation of COVID-19 symptoms was 2.0 days in high dose group versus 6.0 days in the placebo group (HR?=?3.08, 95% CI 0.968–9.818). SIM0417 plus ritonavir were well tolerated with all adverse events in grade?1.

Interpretation

SIM0417 plus ritonavir was generally well tolerated. The efficacy of SIM0417 showed a monotonic dose–response relationship, and the 750?mg SIM0417 plus 100?mg ritonavir was selected as the recommended clinical dose.

Funding

The study was funded by Jiangsu Simcere Pharmaceutical Co., Ltd.

Substances (2)

Related products
Procduct Name CAS Molecular Formula Supplier Price
Ritonavir 155213-67-5 C37H48N6O5S2 695 suppliers $5.00-$1624.00
SARS-CoV-2-IN-41) 2920904-06-7 C22H30F3N5O4S2 11 suppliers Inquiry

Similar articles

IF:98.4

Dutasteride in localised prostate cancer management: the REDEEM randomised, double-blind, placebo-controlled trial.

The Lancet Neil E Fleshner, M Scott Lucia,etc Published: 24 March 2012
IF:6.6

Effects of folic acid and zinc sulfate on male factor subfertility: a double-blind, randomized, placebo-controlled trial

Fertility and sterility Wai Yee Wong M.D, Ph.D. ,etc Published: 1 March 2002
天等县| 隆尧县| 永吉县| 宿州市| 务川| 新兴县| 科技| 兴文县| 甘泉县| 建湖县| 凤庆县| 综艺| 阳西县| 罗定市| 泰来县| 准格尔旗| 长春市| 专栏| 乃东县| 张家界市| 汝阳县| 梧州市| 石景山区| 孝感市| 民勤县| 体育| 于田县| 花莲市| 开阳县| 湛江市| 安阳县| 灵丘县| 中山市| 广平县| 丘北县| 商都县| 独山县| 黄梅县| 亚东县| 台东市| 横山县|